3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
94
Prostatic Neoplasms, Castration-Resistant
10
Neoplasm Metastasis
8
Breast Neoplasms
8
Neoplasms
7
Triple Negative Breast Neoplasms
4
Metastatic Castration-Resistant Prostate Cancer
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Bulbo-Spinal Atrophy, X-Linked
3
Adenocarcinoma
3
mCRPC
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Prostate Adenocarcinoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Bites and Stings
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Interventions
pembrolizumab
7
Nivolumab
7
Specimen Handling
6
Mitomycin
6
Magnetic Resonance Spectroscopy
6
Capecitabine
6
Radiotherapy
5
Fluorouracil
4
Drug Therapy
4
Biopsy
4
Radiation
3
Paclitaxel
3
Ipilimumab
3
Fluorodeoxyglucose F18
3
Carboplatin
3
dehydroftorafur
2
atezolizumab
2
aldesleukin
2
Tomography, X-Ray Computed
2
Sigmoidoscopy
2
Radiotherapy, Intensity-Modulated
2
Proctoscopy
2
Mitozytrex
2
Colonoscopy
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
spartalizumab
1
enzalutamide
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
enzalutamide
×
1 year
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts